<DOC>
	<DOC>NCT00335894</DOC>
	<brief_summary>Multicenter, prospective, randomized, investigator blind, controlled clinical trial. Two parallel groups, one receiving the test drug hMG (hMG-IBSA, IBSA Institut Biochimique sa) and the other the reference drug hMG (Menopur, Ferring Pharmaceuticals, Inc.).</brief_summary>
	<brief_title>Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF).</brief_title>
	<detailed_description>The purpose of the study is to evaluate the clinical efficacy and general tolerability of two different subcutaneous hMG preparations (hMG-IBSA, IBSA vs Menopur, Ferring Pharmaceuticals, Inc.) when administered to patients undergoing controlled ovarian stimulation for IVF.</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<criteria>Women undergoing ovarian stimulation for IVF with or without ICSI (intracytoplasmic sperm injection) and with the following characteristics: Voluntary given informed consent to study participation in writing encompassing consent to data recording and verification procedures; &gt; 18/= and &lt; 37 years old; BMI between 18 and 28 kg/m2; Less than 3 previous completed IVF cycles; Basal FSH level less than 10 IU/L once within 6 months prior to the study; Within 12 month of the beginning of the study, uterine cavity consistent with expected normal function as assessed through a hysterosalpingogram, or sonohysterogram, or hysteroscopic examination or TVUS; Normal or clinically insignificant haematology and blood chemistry values. Primary ovarian failure or women known as poor responders; Signs of PCO, according to the Rotterdam Criteria; At least one ovary inaccessible for oocyte retrieval; One or more ovarian cysts &gt; 10 mm; Hydrosalpinx that have not been surgically removed or ligated; Stage III or IV endometriosis; Patients affected by pathologies associated with any contraindication of being pregnant; Hypersensitivity to the study medication; Abnormal bleeding of undetermined origin; Uncontrolled thyroid or adrenal dysfunction; Neoplasias; PAP smear III within the last 2 years; Severe impairment of the renal and/or hepatic functions; Lactation; Hyperprolactinaemia; Participation in a concurrent clinical trial or in another trial within the past four weeks; Use of concomitant medication that might interfere with study evaluations.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Infertility</keyword>
	<keyword>IVF</keyword>
	<keyword>ART</keyword>
	<keyword>hMG</keyword>
</DOC>